Table 5. Practical use of ASK-12 in clinical setting.
| Case | Age | Sex | Treatment regimen, dose/day, cost* (yen)/month | ASK-12 | ACT | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | pre | post | pre | post | |||||
| 1 | 34 | F | BUD/FM 160 (DPI), 2 blister-bid, 3,451.0 | FF/VI 100 (DPI), 1 blister-qd, 1,796.2 | 31 | 26 | 18 | 19 | ||
| 2 | 42 | F | FP/SM 250 (DPI), 1 puff-bid, 2,139.8 | FF/VI 100 (DPI), 1 blister-qd, 1,796.2 | 31 | 15 | 12 | 21 | ||
| 3 | 28 | M | BDP-HFA 100 (MDI), 2 puff-bid, 1,192.1 | CIC-HFA200 (MDI), 2 puff-qd, 743.2 | 36 | 32 | 13 | 16 | ||
| 4 | 41 | M | BDP-HFA 100 (MDI), 2 puff-bid, 1,192.1 | CIC-HFA200 (MDI), 2 puff-qd, 743.2 | 27 | 28 | 23 | 23 | ||
| 5 | 46 | F | BUD/FM 160 (DPI), 2 blister-bid, 3,451.0 | FF/VI 100 (DPI), 1 blister-qd, 1,796.2 | 28 | 22 | 22 | 25 | ||
| 6 | 47 | F | FP/SM 250 (DPI), 1 blister-bid, 2,139.8 | FF/VI 100 (DPI), 1 blister-qd, 1,796.2 | 29 | 22 | 23 | 25 | ||
| 7 | 45 | M | BUD/FM 160 (DPI), 2 blister-bid, 3,451.0 | FF/VI 100 (DPI), 1 blister-qd, 1,796.2 | 27 | 21 | 23 | 23 | ||
| 8 | 18 | F | BUD/FM 160 (DPI), 2 blister-bid, 3,451.0 | FF/VI 100 (DPI), 1 blister-qd, 1,796.2 | 42 | 20 | 13 | 25 | ||
*, 30% copayment according to the health insurance system of Japan. BUD/FM, budesonide/formoterol; FF/VI, fluticasone furoate/vilanterol; FP/SM, fluticasone propionate/salmeterol; BDP, beclomethasone dipropionate; CIC, ciclesonide; HFA, hydrofluoroalkane propellant; DPI, dry powder inhaler.